By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

The Reverend Richard Andrew, president of the Methodist Conference and chair of the Darlington Methodist District, is urging men to undergo prostate cancer checks after his own diagnosis.

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments ...

Data from Vista Health, a leading UK provider of private diagnostic services, has revealed the worrying knowledge gap when it comes to the prostate, as 26 percent of men do not know what their ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...

Radiopharmaceutical developer Telix Pharmaceuticals Ltd (ASX:TLX) is expanding its push into AI-enabled cancer imaging ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Testicular cancer is one of the most common cancers affecting young men, especially those between the ages of 20 and 40.